Viking Therapeutics Inc. (VKTX) Statistics & Valuation Metrics - Stocknear

Viking Therapeutics Inc.

NASDAQ: VKTX · Real-Time Price · USD
29.72
1.84 (6.60%)
At close: Oct 03, 2025, 3:59 PM
29.90
0.61%
After-hours: Oct 03, 2025, 07:58 PM EDT

Viking Therapeutics Statistics

Share Statistics

Viking Therapeutics has 112.44M shares outstanding. The number of shares has increased by 0.91% in one year.

112.44M
0.91%
0.12%
63.81%
109.09M
35,679
0.57%

Short Selling Information

The latest short interest is 27.01M, so 24.02% of the outstanding shares have been sold short.

27.01M
24.02%
28.82%
5.4

Valuation Ratios

The PE ratio is -39.9 and the forward PE ratio is -8.91. Viking Therapeutics's PEG ratio is -3.63.

-39.9
-8.91
0
466.2
4.98
-49.98
-3.63
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Viking Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 33.09, with a Debt / Equity ratio of 0.

33.09
33.09
0
-0.01
-0.01
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-2.44M
45
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by -54.25% in the last 52 weeks. The beta is 0.64, so Viking Therapeutics's price volatility has been higher than the market average.

0.64
-54.25%
29.44
29.94
60.14
6,242,369

Income Statement

n/a
n/a
-150.92M
-109.96M
-109.52M
-109.87M
-1.01
Full Income Statement

Balance Sheet

The company has 26.68M in cash and 1.12M in debt, giving a net cash position of 25.56M.

26.68M
1.12M
25.56M
-487.91M
827.85M
795.04M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -87.79M and capital expenditures 0, giving a free cash flow of -87.79M.

-87.79M
n/a
-87.79M
-0.81
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

VKTX does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for VKTX is $99, which is 233.1% higher than the current price. The consensus rating is "Buy".

$99
233.1%
Buy
12
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

51.57
2